Category Press Releases

Poxel to Gain Increased Royalties from Sumitomo Pharma for TWYMEEG Sales in Japan

Poxel Achieves Milestone with TWYMEEG® Sales in Japan, Secures Royalties and Sales-Based Payments Poxel, a clinical-stage biopharmaceutical company focused on innovative treatments for chronic serious diseases with metabolic pathophysiology—including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders—has announced a significant…

Read MorePoxel to Gain Increased Royalties from Sumitomo Pharma for TWYMEEG Sales in Japan

MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available

MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available Otsuka Pharmaceutical and Ai-BrainScience Inc. have announced the launch of MIREVO®, a pioneering neuropsychological testing program designed to support medical treatment for dementia. As of January 1, 2025, MIREVO® has…

Read MoreMIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available

Pharma Partners Gilead and LEO Pharma to Accelerate Oral STAT6 Program for Inflammatory Diseases

Pharma Partners Gilead and LEO Pharma Forge Strategic Partnership to Advance Oral STAT6 Program for Inflammatory Diseases Pharma Partners Gilead Sciences and LEO Pharma today announced a groundbreaking strategic partnership designed to accelerate the development and commercialization of LEO Pharma’s…

Read MorePharma Partners Gilead and LEO Pharma to Accelerate Oral STAT6 Program for Inflammatory Diseases

Pharmaceutical Supply Chain Initiative Proudly Welcomes WuXi AppTec as Strategic Partner

WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative to Strengthen Responsible Practices and Supply Chain Resilience Pharmaceutical Supply WuXi AppTec, a global leader providing comprehensive research, development, and manufacturing services to the pharmaceutical and life sciences industries, has announced its…

Read MorePharmaceutical Supply Chain Initiative Proudly Welcomes WuXi AppTec as Strategic Partner

Ailux Biologics Triumphantly UCB Collaborates with XtalPi Division to Revolutionize AI-Powered Biologics

Ailux Biologics UCB\u2019s Strategic Collaboration with Ailux Biologics Ailux Biologics UCB, a leading global biopharmaceutical company, and XtalPi, an industry pioneer in AI-powered drug discovery, have announced a landmark license agreement involving XtalFold™, an advanced biologics AI platform. Developed by…

Read MoreAilux Biologics Triumphantly UCB Collaborates with XtalPi Division to Revolutionize AI-Powered Biologics

Breakthrough Cardiometabolic Disease Treatments Valo Health and Novo Nordisk Expand Collaboration

Novo Nordisk and Valo Health Expand Partnership to Accelerate Cardiometabolic Disease Treatment Discovery Novo Nordisk A/S and Valo Health have announced a significant expansion of their collaboration aimed at discovering and developing innovative treatments for cardiometabolic diseases, including obesity, type…

Read MoreBreakthrough Cardiometabolic Disease Treatments Valo Health and Novo Nordisk Expand Collaboration

Groundbreaking Glucocorticoid Treatment in Congenital Adrenal Hyperplasia Neurocrine Biosciences Publishes Study $10 Million

Impact of High-Dose Glucocorticoid Therapy on Long-Term Health Neurocrine Biosciences has announced the publication of a comprehensive narrative review exploring the complexities of traditional glucocorticoid (GC) treatment for classic congenital adrenal hyperplasia (CAH) and the potential advantages of introducing novel…

Read MoreGroundbreaking Glucocorticoid Treatment in Congenital Adrenal Hyperplasia Neurocrine Biosciences Publishes Study $10 Million

Announces Breakthrough G-Rex® Grant: $125,000 Awarded to Seattle Children’s Therapeutics

Children’s Therapeutics ScaleReady Partners with Industry Leaders to Support Seattle Announces Children’s Therapeutics ScaleReady, in partnership with Wilson Wolf Manufacturing and Bio-Techne Corporation, has announced that Seattle Children’s Therapeutics, a division of the prestigious Seattle Children’s Research Institute, has been…

Read MoreAnnounces Breakthrough G-Rex® Grant: $125,000 Awarded to Seattle Children’s Therapeutics

Bio-Techne Scores Major Victory in 2 Reverse Engineering Claim Against Miltenyi Biotec

Bio-Techne Prevails in Second Case Against Miltenyi Biotec for Reverse Engineering of Antibodies Corporation announced today that it has successfully won another legal claim against Miltenyi Biotec B.V. & Co. KG, which allegedly commercialized antibodies that were developed by reverse…

Read MoreBio-Techne Scores Major Victory in 2 Reverse Engineering Claim Against Miltenyi Biotec